AI Article Synopsis
- Atrial fibrillation (AF) significantly raises stroke risk, leading to the need for careful consideration of anticoagulation therapy, which can also increase bleeding risk in some patients.
- A review of literature identified several risk stratification tools, with CHADS, CHADS-VASc, and ABC scores being most effective for predicting thromboembolic risk, while HAS-BLED is noted for predicting bleeding risk.
- The study highlights a need for further research to improve risk prediction tools, particularly incorporating imaging and biomarker data for better accuracy.
Article Abstract
Background: Atrial fibrillation (AF) is a common cardiac arrhythmia that increases the risk of stroke. Medical therapy for decreasing stroke risk involves anticoagulation, which may increase bleeding risk for certain patients. In determining the optimal therapy for stroke prevention for patients with AF, clinicians use tools with various clinical, imaging and patient characteristics to weigh stroke risk against therapy-associated bleeding risk.
Aim: This article reviews published literature and summarizes available risk stratification tools for stroke and bleeding prediction in patients with AF.
Methods: We searched for English-language studies in PubMed, Embase and the Cochrane Database of Systematic Reviews published between 1 January 2000 and 14 February 2018. Two reviewers screened citations for studies that examined tools for predicting thromboembolic and bleeding risks in patients with AF. Data regarding study design, patient characteristics, interventions, outcomes, quality, and applicability were extracted.
Results: Sixty-one studies were relevant to predicting thromboembolic risk and 38 to predicting bleeding risk. Data suggest that CHADS, CHADS-VASc and the age, biomarkers, and clinical history (ABC) risk scores have the best evidence for predicting thromboembolic risk (moderate strength of evidence for limited prediction ability of each score) and that HAS-BLED has the best evidence for predicting bleeding risk (moderate strength of evidence).
Limitations: Studies were heterogeneous in methodology and populations of interest, setting, interventions and outcomes analysed.
Conclusion: CHADS, CHADS-VASc and ABC scores have the best prediction for stroke events, and HAS-BLED provides the best prediction for bleeding risk. Future studies should define the role of imaging tools and biomarkers in enhancing the accuracy of risk prediction tools.
Primary Funding Source: Patient-Centered Outcomes Research Institute (PROSPERO #CRD42017069999).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6754740 | PMC |
| http://dx.doi.org/10.1055/s-0038-1675400 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Rise and Fall of C-Reactive Protein: Can it Predict Immune Checkpoint Inhibitor-Associated Venous Thromboembolism?
JACC CardioOncol
December 2024
Department of Medicine, University of Ottawa at The Ottawa Hospital and Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Circulating tumor DNA: the dawn of new, clinically scalable biomarkers for thromboembolism.
J Thromb Haemost
January 2025
Department of Medicine, Memorial Sloan Kettering Cancer Center. Electronic address:
From Cell Interactions to Bedside Practice: Complete Blood Count-Derived Biomarkers with Diagnostic and Prognostic Potential in Venous Thromboembolism.
J Clin Med
January 2025
Department of Pathophysiology, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540142 Targu Mures, Romania.
Venous thromboembolism (VTE), encompassing deep vein thrombosis and pulmonary embolism, is a significant burden on health and economic systems worldwide. Improved VTE management calls for the integration of biomarkers into diagnostic algorithms and scoring systems for risk assessment, possible complications, and mortality. This literature review discusses novel biomarkers with potential diagnostic and prognostic value in personalized VTE management.
View Article and Find Full Text PDFRefining Stroke Risk Assessment in Patients with Device-Detected Atrial Fibrillation.
J Clin Med
December 2024
Department of Cardiology, Esbjerg Hospital-University Hospital of Southern Denmark, Finsensgade 35, DK-6700 Esbjerg, Denmark.
Article Synopsis
- Clinical atrial fibrillation (AF) significantly raises the risk of stroke and systemic embolism, but treatment with oral anticoagulants can lower this risk while increasing the chance of major bleeding.
- Device-detected atrial fibrillation (DDAF) also poses a stroke risk, though lower than clinical AF, with studies showing that direct oral anticoagulation can reduce stroke risk for DDAF patients but similarly heightens bleeding risk.
- The challenge persists in determining how to effectively manage the balance between reducing thromboembolic risk and the increased risk of bleeding for DDAF patients, as well as identifying those who would benefit most from anticoagulant therapy.
Chemotherapy alters thrombomodulin and factor VIIIc expression resulting in acquired activated protein C resistance and enhanced thrombin generation in cancer associated thrombosis.
Thromb Res
December 2024
Department of Obstetrics and Gynaecology, Trinity College Dublin, Dublin, Ireland; Trinity St. James's Cancer Institute, Dublin, Ireland. Electronic address:
Background: Tumour type, treatment and patient related factors contribute to cancer associated venous thromboembolism (VTE), however, the role of each factor and the mechanisms involved are not understood.
Aim: To assess the role of the tumour, and of chemotherapy, in mediating the procoagulant response associated with VTE in gynaecological cancer patients.
Methods: Gynaecological cancer patients who developed VTE during follow-up (n = 59) (VTE+) were matched with treatment naïve(treatment (-)(VTE-)(n = 120) and chemotherapy treated patients(treatment (+)(VTE-) (n = 57)).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!